8-K - CTSO - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the SecuritiesExchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2025

CYTOSORBENTS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	001-36792	98-0373793
(State or other jurisdiction <br><br>of incorporation)	(Commission <br><br>File Number)	(IRS Employer<br><br> Identification No.)
305<br> College Road East, Princeton, New<br> Jersey	08540
---	---
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including

area code:(732) 329-8885

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	CTSO	The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07	Submission of Matters to a Vote of Security Holders

CytoSorbents Corporation (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 12, 2025. At the Annual Meeting, the following matters were submitted to a vote of stockholders:

1.	The election of five (5) directors to serve until the Company’s 2026 Annual Meeting of Stockholders, or until their respective successors<br>are elected, except in the case of the death, resignation or removal of any director;
2.	The approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant<br>to Item 402 of Regulation S-K; and
---	---
3.	The ratification of the appointment of WithumSmith+Brown, PC, as the Company’s independent registered public accounting firm for<br>the fiscal year ending December 31, 2025.
---	---

At the close of business on April 17, 2025, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 62,610,376 shares of the Company’s Common Stock outstanding and entitled to vote at the Annual Meeting. The holders of 40,071,481 shares of the Company’s Common Stock were represented in person or by proxy at the Annual Meeting, constituting a quorum.

At the Annual Meeting, (i) the five (5) directors were elected, (ii) the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K, was approved, on a non-binding, advisory basis, and (iii) the appointment of the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified.

Proposal No. 1— Election of Directors

The vote with respect to the election of directors was as follows:

Nominees
Dr. Phillip P. Chan	21,479,032	1,107,546	64,976	17,419,927
Dr. Edward R. Jones	19,790,544	2,791,100	69,910	17,419,927
Michael Bator	19,687,559	2,705,796	258,199	17,419,927
Alan D. Sobel	19,313,170	3,319,370	19,014	17,419,927
Jiny Kim	21,388,189	913,647	349,718	17,419,927

Proposal No. 2 — Approval of the Compensation of the Company’s Named Executive Officers

The vote with respect to the approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K was as follows:

For		Against		Abstain		Broker Non-Votes
	18,189,951		1,720,512		2,741,091		17,419,927

Proposal No. 3 — Ratification of the Appointment of Independent Registered Public Accounting Firm

The vote with respect to the ratification of the appointment of WithumSmith+Brown, PC, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was as follows:

For		Against		Abstain
	39,485,868		553,680		31,933

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoSorbents Corporation
By:	/s/<br> Dr. Phillip P. Chan
	Name:	Dr. Phillip P. Chan
	Title:	Chief Executive Officer